9 December 2016 EMA/CAT/2434/2017 Inspections, Human Medicines Pharmacovigilance & Committees Division

Committee for Advanced Therapies (CAT) Minutes for the meeting on 03-04 November 2016

Chair: Paula Salmikangas - Vice-chair: Martina Schüßler-Lenz 03 November 2016, 09:00 – 18:00, room 03-E 04 November 2016, 09:00 – 13:00, room 03-E

Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised. Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

Table of contents 1.

Introduction

1.1.

Welcome and declarations of interest of members, alternates and experts ............ 5

1.2.

Adoption of agenda................................................................................................. 5

1.3.

Adoption of the minutes ......................................................................................... 5

2.

Evaluation of ATMPs

2.1.

Opinions ................................................................................................................. 5

2.2.

Oral explanations ................................................................................................... 5

2.3.

D180 List of Outstanding Issues ............................................................................. 5

2.4.

D120 List of Questions ............................................................................................ 5

2.5.

Day 80 Assessment Reports ................................................................................... 5

2.6.

Ongoing initial full application ................................................................................ 6

2.7.

New applications .................................................................................................... 6

2.8.

Withdrawal of initial marketing authorisation application ...................................... 6

2.9.

Re-examination of initial application procedure under Article 9(2) of Regulation No. 726/2004 ......................................................................................................... 6

2.10.

GMP and GCP inspections requests ......................................................................... 6

2.11.

Type II Variations ................................................................................................... 6

2.12.

Other post-authorisation activities ......................................................................... 6

2.12.1.

Glybera - alipogene tiparvovec; Orphan; EMEA/H/C/002145 - SOB 002.5 ......................... 6

2.12.2.

Glybera – alipogene tiparvovec; Orphan; EMA/H/C/002145 – S/57 Annual Re-Assessment (ANN 011) ................................................................................................................ 6

3.

Certification of ATMPs

3.1.

Opinions ................................................................................................................. 7

3.2.

Day 60 Evaluation Reports ...................................................................................... 7

3.3.

Ongoing initial application ...................................................................................... 7

3.4.

New applications .................................................................................................... 7

4.

Scientific Recommendation on Classification of ATMPs

4.1.

New Requests – Appointment of CAT Co-ordinators ............................................... 7

4.1.1.

Bone marrow-derived lineage-negative heterogenic stem and progenitor cells; EMA/H0004703 ......................................................................................................... 7

4.1.2.

Leukocytes with cancer killing activity; EMA/H0004704 .................................................. 7

4.2.

Day 30 Co-ordinators’ First Reports ........................................................................ 8

4.2.1.

Bone marrow derived mesenchymal cells (MSCs); EMA/H004688 .................................... 8

4.3.

Day 60 Co-ordinators’ revised reports following List of Questions ......................... 8

4.4.

Finalisation of Procedure ........................................................................................ 8

4.4.1.

Autologous bone marrow-derived non-haematopoietic stem cells; EMA/H004661/001 ........ 8

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

5

5

7

7

Page 2/18

4.4.2.

Anti-BCMA (B-cell Maturation Antigen) Chimeric Antigen Receptor T cells; EMA/H004662/001 .................................................................................................... 8

4.4.3.

Wharton’s jelly derived mesenchymal stem cells; EMA/H004676/001 ............................... 8

4.4.4.

Modified vaccinia virus Ankara encoding human mucin 1 and interleukin 2; EMA/H004658/001 .................................................................................................... 9

4.4.5.

Autologous human adipose mesenchymal stromal cells; EMA/H004677/001 ...................... 9

4.4.6.

Autologous skin cell suspension; EMA/H004679/001 ...................................................... 9

4.4.7.

Rilimogene galvacirepved and rilimogene glafolivec; EMA/H004657/001 .......................... 9

4.5.

Follow-ups and Guidance ........................................................................................ 9

5.

Scientific Advice

5.1.

New SAs – Appointment of CAT Rapporteur .......................................................... 10

5.2.

CAT Rapporteurs’ Reports ..................................................................................... 10

5.3.

List of Issues ........................................................................................................ 10

5.4.

Finalisation of scientific advice procedures .......................................................... 10

6.

Pre-Authorisation Activities

6.1.

Paediatric Investigation Plan (PIP) ...................................................................... 10

6.2.

ITF Briefing Meetings in the field of ATMPs .......................................................... 10

6.3.

Priority Medicines (PRIME) – Eligibility requests .................................................. 10

6.3.1.

Month 0 - Start of the procedure ............................................................................... 10

6.3.2.

Month 1 – Discussion of eligibility .............................................................................. 10

6.3.3.

Month 2 – Recommendation of eligibility..................................................................... 10

6.3.4.

Month 3 – Nomination of Rapporteurs ........................................................................ 10

6.3.5.

Ongoing support ................................................................................................... 10

7.

Organisational, regulatory and methodological matters

7.1.

Mandate and organisation of the CAT ................................................................... 10

7.1.1.

CAT membership ..................................................................................................... 10

7.1.2.

Strategic Review & Learning meeting ......................................................................... 10

7.2.

Coordination with EMA Scientific Committees....................................................... 11

7.2.1.

Committee for Medicinal Products for Human Use (CHMP)............................................. 11

7.3.

Coordination with EMA Working Parties/Working Groups/Drafting Groups ......... 11

7.3.1.

Post-authorisation efficacy study (PAES) - scientific guidance ........................................ 11

7.4.

Cooperation within the EU regulatory network ..................................................... 11

7.4.1.

Guideline on Good Pharmacovigilance Practices (GVP) – Module V – Risk management systems (rev. 2) ...................................................................................................... 11

7.5.

Cooperation with international regulators ............................................................ 12

7.6.

CAT Work Plan ...................................................................................................... 12

7.6.1.

CAT 2017 Work Plan ................................................................................................ 12

7.6.2.

Guideline on requirements for investigational ATMPs .................................................... 12

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

10

10

10

Page 3/18

7.6.3.

Questions and Answers document on minimally manipulated ATMPs .............................. 12

7.7.

Planning and reporting ......................................................................................... 13

7.7.1.

Management Board data gathering exercise - CAT horizontal data collection ................... 13

7.8.

Others .................................................................................................................. 13

7.8.1.

EMA-EuropaBio Information Day 22 November 2016, Canary Wharf, London................... 13

7.8.2.

EMA-European Biopharmaceutical Enterprises (EBE). Annual regulatory conference, 16 December 2016, Canary Wharf, London ..................................................................... 13

8.

Any other business

13

9.

Explanatory notes

14

10.

List of participants

17

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 4/18

1.

Introduction

1.1.

Welcome and declarations of interest of members, alternates and experts In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified. Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2.

Adoption of agenda The CAT agenda for the 03 - 04 November 2016 meeting was adopted with one addition under agenda point 6.3.5.

1.3.

Adoption of the minutes The CAT minutes of the 06 - 07 October 2016 meeting were adopted with one change to section point 5.2.1.

2.

Evaluation of ATMPs

2.1.

Opinions No items

2.2.

Oral explanations No items

2.3.

D180 List of Outstanding Issues No items

2.4.

D120 List of Questions No items

2.5.

Day 80 Assessment Reports No items

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 5/18

2.6.

Ongoing initial full application No items

2.7.

New applications No items

2.8.

Withdrawal of initial marketing authorisation application No items

2.9.

Re-examination of initial application procedure under Article 9(2) of Regulation No. 726/2004 No items

2.10.

GMP and GCP inspections requests No items

2.11.

Type II Variations No items

2.12.

Other post-authorisation activities

2.12.1.

Glybera - alipogene tiparvovec; Orphan; EMEA/H/C/002145 - SOB 002.5 UniQure Biopharma B.V. Rapporteur: Christiane Niederlaender; CHMP Coordinator: Greg Markey; PRAC Rapporteur: Julie Williams Scope: an open label, multi-centre trial of Glybera (alipogene tiparvovec) for the treatment of LPLD Patients – Protocol amendment. This is a phase III/IV prospective, interventional, randomised, open-label, parallel group study evaluating the clinical response as well as the dynamics of postprandial chylomicron metabolism in patients treated with Glybera with and without immunosuppressants. Action: for adoption Documents: Assessment report Request for Supplementary information CAT discussed the Rapporteur’s assessment report. Two changes to the protocol of the postauthorisation study, proposed by the MAH , were considered substantial and further clarifications are needed. CAT adopted a request of supplementary information.

2.12.2.

Glybera – alipogene tiparvovec; Orphan; EMA/H/C/002145 – S/57 Annual Re-Assessment (ANN 011) UniQure Biopharma B.V. Rapporteur: Christiane Niederlaender; CHMP Coordinator: Greg Markey; PRAC Rapporteur: Julie Williams

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 6/18

Scope: Clinical and PhV: timetable for 4th Annual Reassessment. SOB002.6 (Assessment of postprandial chylomicron metabolism in at least 12 patients before 12 months and 24 months after treatment with Glybera to be chosen in addition to the patients included in study CT-AMT.011.02; and eight healthy subjects in the second study) will be assessed with the Annual reassessment S/57. Action: for adoption The review timetable was adopted.

3.

Certification of ATMPs

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1.

Opinions No items

3.2.

Day 60 Evaluation Reports

3.3.

Ongoing initial application No items

3.4.

New applications No items

4.

Scientific Recommendation on Classification of ATMPs

4.1.

New Requests – Appointment of CAT Co-ordinators

4.1.1.

Bone marrow-derived lineage-negative heterogenic stem and progenitor cells; EMA/H0004703 Intended for the treatment of amyotrophic lateral sclerosis in adults Scope: appointment of CAT Co-ordinator and adoption of timetable Action: for adoption Documents: Request received 24.10.16 Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.2.

Leukocytes with cancer killing activity; EMA/H0004704 Intended for the treatment of metastatic pancreatic ductal adeno carcinoma Scope: appointment of CAT Co-ordinator and adoption of timetable Action: for adoption Documents:

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 7/18

Request received 24.10.16 Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.2.

Day 30 Co-ordinators’ First Reports

4.2.1.

Bone marrow derived mesenchymal cells (MSCs); EMA/H004688 Intended for acute graft versus host disease grades III and IV resistant to the first line of treatment Scope: Scientific Recommendation Action: for adoption CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.3.

Day 60 Co-ordinators’ revised reports following List of Questions No items

4.4.

Finalisation of Procedure

4.4.1.

Autologous bone marrow-derived non-haematopoietic stem cells; EMA/H004661/001 Intended for the treatment of multiple sclerosis Scope: no comments from the EC Action: for information Document: ATMP classification report The information was noted.

4.4.2.

Anti-BCMA (B-cell Maturation Antigen) Chimeric Antigen Receptor T cells; EMA/H004662/001 Intended for the treatment of multiple myeloma and B cell lymphoma Scope: no comments from the EC Action: for information Document: ATMP classification report The information was noted.

4.4.3.

Wharton’s jelly derived mesenchymal stem cells; EMA/H004676/001 Intended for the treatment of acute myocardial infarction, chonic ishemic heart failure and no-option critical limb ischemia

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 8/18

Scope: no comments from the EC Action: for information Document: ATMP classification report The information was noted.

4.4.4.

Modified vaccinia virus Ankara encoding human mucin 1 and interleukin 2; EMA/H004658/001 Intended for the treatment of advanced non-squamous non-small cell lung cancer Scope: no comments from the EC Action: for information Document: ATMP classification report The information was noted.

4.4.5.

Autologous human adipose mesenchymal stromal cells; EMA/H004677/001 Intended for the cardiac repair after myocardial infarction Scope: no comments from the EC Action: for information Document: ATMP classification report The information was noted.

4.4.6.

Autologous skin cell suspension; EMA/H004679/001 Intended for the treatment of burns, donor sites and other wounds Scope: no comments from the EC Action: for information Document: ATMP classification report The information was noted.

4.4.7.

Rilimogene galvacirepved and rilimogene glafolivec; EMA/H004657/001 Intended for the treatment of metastatic, castrate-resistant Prostate cancer Scope: no comments from the EC Action: for information Document: ATMP classification report The information was noted.

4.5.

Follow-ups and Guidance No items

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 9/18

5.

Scientific Advice

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1.

New SAs – Appointment of CAT Rapporteur

5.2.

CAT Rapporteurs’ Reports

5.3.

List of Issues

5.4.

Finalisation of scientific advice procedures

6.

Pre-Authorisation Activities

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1.

Paediatric Investigation Plan (PIP) No items

6.2.

ITF Briefing Meetings in the field of ATMPs

6.3.

Priority Medicines (PRIME) – Eligibility requests

6.3.1.

Month 0 - Start of the procedure

6.3.2.

Month 1 – Discussion of eligibility

6.3.3.

Month 2 – Recommendation of eligibility

6.3.4.

Month 3 – Nomination of Rapporteurs

6.3.5.

Ongoing support

7.

Organisational, regulatory and methodological matters

7.1.

Mandate and organisation of the CAT

7.1.1.

CAT membership Scope: DK – Anne Pastoft - new alternate nominated on 12 October 2016 Action: for information The information was noted

7.1.2.

Strategic Review & Learning meeting CAT Strategic Review & Learning meeting, Dublin, Ireland on 24-25 October 2016

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 10/18

CAT resources: Paula Salmikangas, Maura O’Donovan Scope: oral report on the meeting Action: for information Feedback was provided from the discussion at the Strategic Review & Learning meeting. The slides and minutes of the meeting will become available by end of the month . There was a follow-on discussion on the use of registries / Real World evidence for the approval and post-marketing activities of medicines / ATMPs.

7.2.

Coordination with EMA Scientific Committees

7.2.1.

Committee for Medicinal Products for Human Use (CHMP) Scope: Summary of Outcomes (SoO) for the October 2016 meeting Action: for information Documents: -Summary of Outcomes The information was noted.

7.3.

Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1.

Post-authorisation efficacy study (PAES) - scientific guidance Scope: finalisation of the guidance document Action: for silent adoption Document: -Scientific guidance on post-authorisation efficacy studies -Overview of comments Note: public consultation on the draft PAES scientific guidance ended on the 31 January 2016. Comments have been addressed and the guidance revised The guideline was adopted.

7.4.

Cooperation within the EU regulatory network

7.4.1.

Guideline on Good Pharmacovigilance Practices (GVP) – Module V – Risk management systems (rev. 2) Scope: two-week consultation with EMA committees by 4 November 2016 Action: For information Note: -the document was sent to all CAT members on 21.10.16. -if no major changes are raised, the guidance will be considered endorsed by all committees and sent to the EC for review. -Good Pharmacovigilance Practices (GVP) webpage http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/docum ent_listing_000345.jsp&mid=WC0b01ac058058f32c#section4 The information was noted.

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 11/18

7.5.

Cooperation with international regulators No items

7.6.

CAT Work Plan

7.6.1.

CAT 2017 Work Plan Scope: draft Work Plan 2017 Action: for discussion CAT discussed the workplan and agreed on action points for next year. CAT members were asked to indicate their interest to work on any of the topics identified in the work plan for 2017, either as leader or participant: please inform the CAT secretariat by 1 December 2017. It was noted that the activities from the CAT work plan 2016 will continue if not yet completed (these are not repeated in the 2017 work plan).

7.6.2.

Guideline on requirements for investigational ATMPs CAT drafting groups: Tiina Palomäki (Rapporteur), Ilona Reischl (Rapporteur), Metoda Lipnik-Stangelj, Margarida Menezes Ferreira, Maura O’Donovan, Simona Badoi, Tomáš Boráň, Christiane Niederlaender, Paolo Gasparini, Olli Tenhunen, Marit Hystad, Violaine Closson-Carella, Marcel Hoefnagel, Guido Pantè, Carla Herberts Scope: draft guideline on the non-clinical and clinical parts Action: for discussion Feedback was provided by the Drafting group members: the non-clinical and clinical parts of the guideline are most advanced; for the quality part, the discussions have focused so far on the requirement for cell-based investigational ATMPs. Further drafting groups will be organised to progress the development of this guideline.

7.6.3.

Questions and Answers document on minimally manipulated ATMPs CAT drafting group: Metoda Lipnik-Stangelj, Paula Salmikangas, Tiina Palomäki, Egbert Flory, Margarida Menezes Ferreira, Marit Hystad, Mikuláš Hrubiško Scope: draft Questions & Answers Action: for discussion Note: The Questions-and-Answers document describes the quality, non-clinical and clinical requirements for the marketing authorisation for a minimally manipulated ATMP (e.g. CD34+ cells for cardiac repair). In the answers, a practical explanation will be provided how to use the risk based approach to identify and justify deviations for the standard requirements for cell-based ATMPs as included in Annex I Part IV of Dir. 2001/83/EC. Feedback was provided by the Drafting group members. The document is now ready for comments from the CAT members until 1 December 2017. This will allow for an in-depth discussion and possible adoption of this Q&A in the December CAT meeting.

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 12/18

7.7.

Planning and reporting

7.7.1.

Management Board data gathering exercise - CAT horizontal data collection Scope: update on progress. The project started in March 2014 . The latest part of the projects relate to time spent by committee members/alternates when not acting in their principal role as centralised product rapporteurs/peer reviewers. Action: For information Feedback was provided on the goal and scope of this exercise.

7.8.

Others

7.8.1.

EMA-EuropaBio Information Day 22 November 2016, Canary Wharf, London Scope: EMA-EuropaBio Information Day, 22 November 2016 Action: for information Document: -Agenda The agenda was presented. There are a couple of places if CAT members want to attend this meeting (but no reimbursement is available): please inform the CAT Secretariat.

7.8.2.

EMA-European Biopharmaceutical Enterprises (EBE). Annual regulatory conference, 16 December 2016, Canary Wharf, London Scope: ‘Optimising the development of ATMPs to meet patient needs’ - The fifth annual regulatory conference organised by the European Biopharmaceutical Enterprises (EBE) in collaboration with the European Medicines Agency (EMA) Action: for information Document: -Agenda Note: access to further information here: http://www.ebe-biopharma.eu/calendar/136/46/Optimising-the-Development-of-ATMPs-toMeet-Patient-Needs-The-fifth-annual-regulatory-conference-organised-by-the-EuropeanBiopharmaceutical-Enterprises-EBE-in-collaboration-with-the-European-Medicines-AgencyEMA The agenda was presented. There are a couple of places if CAT members want to attend this meeting (but no reimbursement is available): please inform the CAT Secretariat.

8.

Any other business No items

Date of next CAT meeting: Thursday 08 to Friday 09 December 2016

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 13/18

9.

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Evaluation of ATMPs (section 2) This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.) Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here. The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.) Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee. Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 14/18

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.) This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.) This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.) In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.) This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.) This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, reexamination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3) This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4) This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 15/18

Scientific Advice (section 5) This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6) Paediatric Investigation Plan (PIP) This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days. CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME) This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP. CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7) This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups. Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8) This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/ Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 16/18

10.

List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 03-04 November 2016 meeting. Name

Paula

Role

Member state or

Outcome restriction

Topics on agenda

affiliation

following evaluation of

for which

e-DoI

restrictions apply

Chair

Finland

No interests declared

Alternate

Austria

No restrictions applicable

Salmikangas Martin Brunner

to this meeting Claire Beuneu

Member

Belgium

No interests declared

Belaïd Sekkali

Alternate

Belgium

No interests declared

Mirna Golemovic

Member

Croatia

No interests declared

Tomáš Boráň

Member

Czech Republic

No interests declared

Anne Pastoft

Alternate

Denmark

No interests declared

Toivo Maimets

Member

Estonia

No interests declared

Tiina Palomäki

Member

Finland

No interests declared

Olli Tenhunen

Alternate

Finland

No interests declared

Violaine Closson

Member

France

No interests declared

Martina

Member (Vice-

Germany

No interests declared

Schüssler-Lenz

Chair)

Angeliki Roboti

Alternate

Greece

No interests declared

Krisztian Fodor

Member

Hungary

No interests declared

Maura

Member

Ireland

No interests declared

Romaldas

Member (CHMP

Lithuania

No restrictions applicable

Mačiulaitis

member)-via TC

Guy Berchem

Alternate

O'Donovan to this meeting Luxembourg

(replacing

No restrictions applicable to this meeting

CHMP member) Johannes

Member

Netherlands

No interests declared

Marit Hystad

Member

Norway

No interests declared

Rune Kjeken

Alternate

Norway

No restrictions applicable

Dariusz

Member

Poland

Hendrikus Ovelgönne

to this meeting Śladowski

No restrictions applicable to this meeting

Simona Badoi

Member

Romania

No interests declared

Ján Kyselovič

Alternate

Slovakia

No interests declared

Metoda Lipnik-

Member

Slovenia

No interests declared

Member (CHMP

Spain

No interests declared

Stangelj Sol Ruiz

co-opted

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 17/18

Name

Role

Member state or

Outcome restriction

Topics on agenda

affiliation

following evaluation of

for which

e-DoI

restrictions apply

member)-via TC Marcos Timón

Alternate (to

Spain

No interests declared

Member

Sweden

No interests declared

Member

United Kingdom

No interests declared

Member

Healthcare

No restrictions applicable

Professionals'

to this meeting

CHMP representative) Lennart Åkerblom Christiane Niederlaender Marc Turner

Representative Bernd

Member

Gänsbacher

Healthcare

No interests declared

Professionals' Representative

Kieran Breen Michelino Lipucci

Member Alternate

di Paola Mariëtte

Member

Driessens Erik Briers

Alternate

Guido Pantè

Expert - in

Patients'

No restrictions applicable

Representative

to this meeting

Patients'

No restrictions applicable

Representative

to this meeting

Patients'

No restrictions applicable

Representative

to this meeting

Patients'

No restrictions applicable

Representative

to this meeting

Italy

No interests declared

France

No interests declared

Germany

No restrictions applicable

person* Christos Sotirelis

Expert - in person*

Wiebke

Expert - via

Hoppensack

telephone*

Andreea Barbu

Expert - via

to this meeting Sweden

telephone* Sirkku Saarela

Expert - via

No restrictions applicable to this meeting

Finland

No interests declared

Netherlands

No interests declared

Netherlands

No interests declared

telephone* Marcel H.N.

Expert - via

Hoefnagel

telephone*

Marja van de

Expert - via

Bovenkamp

telephone*

A representative from the European Commission attended the meeting Meeting run with support from relevant EMA staff * Experts were only evaluated against the agenda topics or activities they participated in.

Committee for Advanced Therapies (CAT) EMA/CAT/2434/2017

Page 18/18

Minutes of the CAT meeting 3-4 November 2016 - European ...

Dec 9, 2016 - Send a question via our website www.ema.europa.eu/contact ..... Intended for acute graft versus host disease grades III and IV resistant to the ...

257KB Sizes 1 Downloads 411 Views

Recommend Documents

Minutes of the CAT meeting 3-4 November 2016 - European ...
Dec 9, 2016 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of ...... Meeting run with support from relevant EMA staff.

Minutes of the CAT meeting 8-9 December 2016 - European ...
Jan 20, 2017 - Withdrawal of initial marketing authorisation application . ..... Scope: report of the PCPWP/HCPWP workshop on social media (19 September ...

Minutes of the HMPC 21-22 November 2016 meeting - European ...
Jan 31, 2017 - Documents: Presentation; Draft procedure; Template example ... Documents: Procedure for the election of HMPC Chair; Email, 29 Sep 2016; ...

Minutes of the CAT meeting 8-9 December 2016 - European ...
Jan 20, 2017 - Day 60 revised ATMP scientific recommendation (following list of ..... Scope: report of the PCPWP/HCPWP workshop on social media (19 ...

Minutes of the COMP meeting 3-4 November 2016 - European ...
Jan 9, 2017 - Send a question via our website www.ema.europa.eu/contact ...... that the best standard of care was employed by using combination therapies ..... the treatment of patients with graft vs host disease for orphan designation.

Minutes of the COMP meeting 3-4 November 2016 - European ...
Jan 9, 2017 - access to documents within the framework of Regulation (EC) No 1049/2001 as ... Applications for orphan medicinal product designation ...... To establish correctly if there exists a scientific rationale for the development of the.

Minutes of the CHMP meeting 7-10 November 2016 - European ...
Dec 16, 2016 - Initial applications; List of outstanding issues (Day 180; Day 120 for ...... Post-meeting note: The company withdrew the application on 16 ...

Minutes of the HMPC 21-22 November 2016 meeting - European ...
Jan 31, 2017 - Three tea combinations (gastrointestinal disorders, mental stress, to aid sleep) ..... HMPC Q DG to further integrate requirements on PA testing into ... Documents: Work plan 2016 – current status; HMPC work plan tracking tool 2016 .

Minutes of the CHMP meeting 7-10 November 2016 - European ...
Dec 16, 2016 - Furthermore, the PI is brought in line with the latest QRD template version 10.” ...... H. ANNEX H - Product Shared Mailboxes – e-mail address .

Minutes of the CAT meeting 6-8 December 2017 - European ...
Jan 19, 2018 - Guy Berchem. Alternate (to. CHMP representative). Luxembourg. No restrictions applicable to this meeting. N/A. Anthony. Samuel. Alternate (to.

Minutes of the CAT meeting 30-31 October 2017 - European ...
Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that th

Minutes of the CAT meeting 15-17 February 2017 - European ...
by applicants and may also vary during the course of the review. Additional details on some ...... There was a short discussion on resources to CAT and to the CAT secretariat. 7.1.3. Strategic ... A meeting via Adobe Connect will be organised.

Minutes of the CAT meeting 30-31 October 2017 - European ...
This section refers to briefing meetings of the Innovation Task Force and ... The Innovation Task Force (ITF) is a body set up to encourage early dialogue with ...

Minutes of the CAT meeting 6-8 December 2017 - European ...
Jan 19, 2018 - 2017, London, UK. CAT: Martina Schüssler-Lenz. Scope: feedback on the participation of EMA and CAT to the EBE's sixth annual regulatory conference: 'Realising the potential of advanced therapies for patients'. Action: for information.

Minutes of the CAT meeting 15-17 February 2017 - European ...
Send a question via our website www.ema.europa.eu/contact. © European ... and emergency information and procedures prior to the start of the meeting.

Minutes of the PRAC meeting 28 November - European Medicines ...
3.3.1. Direct-acting antivirals (DAAV) indicated for the treatment of hepatitis C (interferon free): ..... Protocols of PASS imposed in the marketing authorisation(s) . ..... Public hearings - procedural and best practice guidance for PRAC members .

Minutes PRAC meeting of 27-30 November 2017 - European ...
Jan 11, 2018 - Minutes of the meeting on 27 – 30 November 2017. Chair: June Raine – Vice-Chair: Almath Spooner. Health and safety information. In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and

CAT agenda of the 8-9 September 2016 meeting - European ...
Sep 8, 2016 - Send a question via our website www.ema.europa.eu/contact ... Page 2/20 ...... on social media – 19 September 2016 (EMA/825257/2015).

CAT agenda of the 8-9 September 2016 meeting - European ...
Sep 8, 2016 - Day 60 Co-ordinators' revised reports following List of Questions . ..... -Clinical: P. Gasparini, B. Klug, M. Hystad, O. Tenhunen (all tbc). 7.3.4. ... Workshop on social media – 19 September 2016 (EMA/825257/2015). -Report of ...

HMPC agenda of the 21-22 November 2016 meeting - European ...
Nov 18, 2016 - Revised EU herbal monographs and list entries for final adoption .......................... 6. 2.2.1. ..... Any other business. 12. 6.1. .... Documents: Email from HMPC Chair, 26 May 2016; Summary in presentation; Summary of. Strategic

Minutes of the CAT meeting 16-17 June 2016 - European Medicines ...
Jul 13, 2016 - Minutes of the meeting on 16-17 June 2016. Chair: Paula ..... Any other business. 16. 8.1. ..... HTA: Health Technology Assessment Bodies.

Minutes PRAC meeting of 27-30 November 2017 - European ...
Jan 11, 2018 - Post-meeting note: The updated additional monitoring list was published on 15/12/2017 on the EMA website (see: Home>Human Regulatory>Human · medicines>Pharmacovigilance>Signal management>List of medicines under additional · monitoring)

HMPC agenda of the 21-22 November 2016 meeting - European ...
Nov 18, 2016 - Joint CVMP/CHMP ad hoc expert group meeting on 3Rs (JEG 3Rs ..... Documents: Email from HMPC Chair, 26 May 2016; Summary in ...

Minutes of the PRAC meeting 26-29 September 2016 - European ...
Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended ...